Introduction {#s1}
============

In the early embryo, secreted morphogens regulating a limited number of signaling pathways carry the task of instructing dynamic and coordinated cell differentiation across the developing tissue. In the day 6.5 mouse embryo, a hierarchy of signaling mediated by BMP, WNT, and NODAL carries the positional information in the epiblast leading to axis formation and germ layer specification ([@bib2]). Each of these morphogens induces the expression of the next ligand (BMP signaling induces WNT expression, and WNT signaling induces NODAL expression), and all induce the expression of their own inhibitors. To what extent this signaling cascade is involved in human gastrulation can now be investigated using in vitro models of early human embryos derived from human embryonic stem cells (hESCs).

We have previously shown that the first step of this signaling hierarchy is conserved in humans and that in response to BMP4, hESCs grown in geometrically confined colonies, self-organize to induce and pattern embryonic and extra-embryonic germ layers. Ectoderm was specified at the center of circular colonies, extra-embryonic tissue at the edge and mesendoderm in between. Molecular signatures of gastrulation, such as the induction of SNAIL and activation of pERK could also be observed ([@bib57]). Consistent with the conservation of the second step of the signaling hierarchy, BMP4, which signals through SMAD1/5/8, was shown to induce the expression of WNT ligands, which can also induce the emergence of a primitive streak and the self-organization of embryonic germ layers in this system ([@bib17]; [@bib32]). We, therefore, termed this system a human gastruloid.

The third pathway, SMAD2/3, which signals on behalf of ACTIVIN and NODAL ligands, has an intriguing role. On the one hand, SMAD2/3 signaling is required for hESC pluripotency maintenance ([@bib24]; [@bib53]). On the other hand, the ACTIVIN/NODAL pathway is necessary for fate specification, acting as a morphogen to pattern the blastula of vertebrate embryos from the amphibian to the mouse ([@bib33]; [@bib38]). The ACTIVIN/NODAL pathway is also necessary for the self-organization of human gastruloids as inhibition of SMAD2/3 signaling blocks primitive streak formation and mesendoderm induction by BMP4 and eliminates anterior mesendoderm fates induced by WNT3A ([@bib57]; [@bib32]). Furthermore, co-presentation of ACTIVIN with WNT3A to micropatterned hESC colonies leads to the induction of the organizer specific marker GOOSECOID, and a functional human primitive streak, which when grafted into chick embryos induces the formation of a secondary axis ([@bib32]).

Despite these findings, the mechanism by which SMAD2/3 signaling can specify both hESC pluripotency and differentiation remains perplexing, and a number of key questions remain unanswered. Among them are: how can a single signaling pathway carry these two opposite functions before and after the onset of gastrulation? To what extent do the dynamics of SMAD signaling affect these readouts? Finally, to what extent do cells have a memory of past signaling?

In this study we aimed to provide highly quantitative answers to these questions by following the dynamics of TGFβ signaling during the self-organization of human gastruloids. Imaging of hESC reporter lines engineered by CRISPR/Cas9-mediated tagging of SMAD1, SMAD2, or SMAD4 demonstrated that each branch of the pathway has distinct signaling dynamics. In response to ACTIVIN, SMAD2 displayed a dramatic transient nuclear translocation, which stood in sharp contrast to the stable BMP4-induced SMAD1 response. ACTIVIN stimulation did induce transient mesendodermal gene transcription, which correlated with SMAD2 dynamics. This induction, however, was not sustained and cells reverted back to pluripotency at later times. Interestingly, pre-presentation of WNT3A to the cells, while not changing SMAD2 dynamics or expression of the pluripotency markers, stabilized the subsequent transcriptional response to ACTIVIN to maintain mesendodermal fates. This implies an unexpected ability of human embryonic stem cells to record their signaling history without overt changes in fate.

Results {#s2}
=======

Gastruloids respond to ACTIVIN stimulation at the colony border {#s2-1}
---------------------------------------------------------------

A functional SMAD2/3 pathway is necessary for both maintenance of pluripotency, as well as differentiation and self-organization of human gastruloids downstream of BMP4 and WNT3A ([@bib57]; [@bib32]). In the context of BMP4 induced differentiation, treatment with a small molecule inhibitor of SMAD2/3 signaling, SB431542 (SB), eliminated all mesendodermal fates, as indicated by the loss of BRA and SOX17 positive cells, leaving only the putative extra-embryonic and ectoderm fates, marked by CDX2 and SOX2 expression, respectively ([Figure 1A](#fig1){ref-type="fig"}) ([@bib57]). Presentation of the downstream morphogen WNT3A induced primitive streak formation at the colony border, and addition of SB in this context removed the SOX17 positive mesendodermal population ([Figure 1A](#fig1){ref-type="fig"}) ([@bib32]). In order to ask whether gastruloid self-organization can be initiated at the ACTIVIN/NODAL point in the signaling hierarchy, we stimulated micropatterned colonies grown in conditioned media with high concentrations of ACTIVIN A (referred to as ACTIVIN throughout this work). In contrast to stimulation with BMP4 and WNT3A, no differentiation was observed after 48 hr with ACTIVIN alone ([Figure 1B](#fig1){ref-type="fig"}). Surprisingly, the lack of differentiation in response to ACTIVIN was not due to a lack of signal sensing, as an increase in nuclear SMAD2/3 was detected by immunofluorescence at the colony border after one hour of stimulation ([Figure 1C--D](#fig1){ref-type="fig"}). We conclude that while SMAD2/3 signaling is necessary for mesendoderm induction downstream of BMP4 and WNT3A in human gastruloids, it is not sufficient to induce it.

![ACTIVIN modifies gastruloid differentiation but it cannot induce it.\
(**A**) Micropatterned colonies in conditioned media treated for with BMP4 (50 ng/mL), BMP4 (50 ng/mL) +SB (10 µM), WNT3A (100 ng/mL), or WNT3A (100 ng/mL) +SB (10 µM) for 48 hr. The colonies were fixed and analyzed by immunofluorescence. Left: SOX2 (cyan), BRA (magenta), CDX2 (yellow). Right: DAPI (green), SOX17 (magenta). (**B**) Micropatterned colonies in conditioned media treated with BMP4 (50 ng/mL), WNT3A (100 ng/mL), or ACTIVIN (100 ng/mL) for 48 hr. The colonies were fixed and analyzed by immunofluorescence. Left: SOX2 (cyan), BRA (magenta), CDX2 (yellow). Right: DAPI (green), SOX17 (magenta). (**C--D**) Micropatterned colonies in conditioned media (CM) treated with ACTIVIN (100 ng/mL) for 1 hr or left untreated. The colonies were fixed and analyzed by immunofluorescence. (**C**) Images: DAPI (red), SMAD2/3 (green). Scale bar, 200 µm. (**D**) Quantification of the mean SMAD2/3 nuclear fluorescence as a function of radial position from the colony edge: CM + ACTIVIN (filled circles), CM (open squares). Error bars represent the standard deviation across n = 5 (CM) and n = 6 (CM + ACTIVIN) colonies from one experiment. All micropatterned culture experiments were performed on at least three separate occasions with similar results.](elife-38279-fig1){#fig1}

Two branches of the TGFβ pathway display different signaling dynamics {#s2-2}
---------------------------------------------------------------------

The inability of ACTIVIN/SMAD2 to induce differentiation stood in stark contrast with the ability of BMP/SMAD1 to induce gastruloid self-organization, including patterning of the mesoderm and endoderm germ layers. This contrast in activity of the two branches of the TGFβ pathway prompted us to assess possible differences in their signaling dynamics. We used CRISPR/Cas9 genome engineering on RUES2 to fluorescently tag the N-terminus of the endogenous receptor-associated, R-SMAD1, with tagRFP (RUES2-RFP-SMAD1) and R-SMAD2 with mCitrine (RUES2-mCit-SMAD2) ([Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). As activation of the pathway leads to the binding of SMAD1 and 2 to the co-SMAD, SMAD4, before nuclear translocation and regulation of gene expression, a GFP-tagged SMAD4 line (RUES2-GFP-SMAD4) was also included ([Figure 2A](#fig2){ref-type="fig"}) ([@bib36]). Each line was also transfected with ePiggyBac transposable elements carrying a nuclear marker (H2B-mCitrine or H2B-mCherry) in order to analyze the response of individual cells ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). N-terminal SMAD fusion proteins were shown to function similarly to endogenous proteins in biochemical and cell-based assays ([@bib43]). Additionally, the SMAD response dynamics measured with our reporter lines, matched the behavior by of the endogenous proteins measured by immunofluorescence and western blotting as discussed below.

![Two branches of the TGFβ pathway display different signaling dynamics.\
(**A**) BMP and ACTIVIN signaling represent the two branches of the TGFβ pathway. BMP signals through R-SMAD1 and ACTIVIN signals through R-SMAD2. R-SMADs form a complex with co-SMAD4 and the complex regulates target gene expression. (**B--C**) RUES2-RFP-SMAD1 grown on micropatterned colonies in E7 and stimulated with BMP4 (50 ng/mL). The response of cells at the colony edge (**B**) and near the colony center (**C**) as a function of time following BMP4 presentation. The intensity range was adjusted to the same minimum and maximum values in all images in both (**B**) and (**C**). Scale bars, 25 µm. (**D**) Average RFP-SMAD1 nuclear signal as a function of radial position within the colony at different time points following BMP4 treatment. The single-cell nuclear RFP-SMAD1 intensity was quantified and normalized to the single-cell H2B-mCitrine signal. Error bars represent the standard deviation over n = 5 colonies from one experiment. (**E--F**) RUES2-mCit-SMAD2 grown on micropatterned colonies in E7 and stimulated with ACTIVIN (10 ng/mL). The response of cells at the colony edge (**E**) and near the colony center (**F**) as a function of time following ACTIVIN presentation. The intensity range was adjusted to the same minimum and maximum values in all images in both (**E**) and (**F**). Scale bars represent 25 µm. (**G**) Average mCitrine-SMAD2 nuclear-to-cytoplasmic signal as a function of radial position within the colony at different time points following ACTIVIN treatment. The single-cell nuclear mCitrine intensity was quantified and normalized to the single-cell cytoplasmic mCitrine signal. Error bars represent the standard deviation over n = 5 colonies from one experiment.](elife-38279-fig2){#fig2}

We began our dynamic studies of the two branches of TGFβ signaling in RUES2 cells grown on micropatterned colonies in chemically-defined medium (TeSR-E7), which is a version of serum-free E8 medium that can maintain hESCs and that lacks any TGFβ ligands ([@bib8]). Therefore, in E7 the exogenous TGFβ levels could be precisely controlled. In response to BMP4, we detected an increase in the SMAD1 nuclear signal that was stable over 12 hr ([Figure 2B--D](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}, [Figure 2---videos 1](#fig2video1){ref-type="video"} and [2](#fig2video2){ref-type="video"}). The SMAD1 response was observed at the colony edge, consistent with our previous immunofluorescence results and our discovery that the TGFβ receptors are localized to the apical surface only at the border of the colony ([@bib57]; [@bib17]). In our previous work we quantified the SMAD1 response detected by immunofluorescence as the number of positive nuclei within the colony ([@bib17]). Although our reporter line allows us to track the level of nuclear SMAD1 in individual cells, as opposed to a binary on/off quantification, we obtain similar results to those shown in [Figure 2D](#fig2){ref-type="fig"} with a binary analysis of the RFP-SMAD1 reporter line ([Figure 2---figure supplement 2C--D](#fig2s2){ref-type="fig"}). In response to ACTIVIN, SMAD2 on the other hand, responded only transiently: a pulse of nuclear translocation over the first 1--2 hr was followed by a gradual decrease over the next 6 hr ([Figure 2E--G](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2E](#fig2s2){ref-type="fig"}, and [Figure 2---video 3](#fig2video3){ref-type="video"}). Interestingly, the long-term SMAD2 nuclear level did not return completely to the pre-stimulus level. As in the case of SMAD1, the SMAD2 response was highest at the colony edge, again consistent with the apical localization of the receptors ([@bib17]).

Single-cell response dynamics reflect the behavior at the edge of gastruloids {#s2-3}
-----------------------------------------------------------------------------

In order to study signaling dynamics at the single-cell level and to eliminate modifier influences on both SMAD branches coming from neighboring cells within the micropatterned colony, we performed the same experiment on dissociated cells grown under regular culture conditions ([Figure 3A](#fig3){ref-type="fig"}). The SMAD1 response to BMP was stable and the level of nuclear RFP-SMAD1 was dependent on the BMP4 ligand concentration in agreement with previous single-cell immunofluorescence measurements ([Figure 3B--C](#fig3){ref-type="fig"}) ([@bib17]). The increase in the average nuclear signal as a function of time resulted from nearly all cells responding to the added BMP4, which is evident in the shift in the histogram of RFP-SMAD1 nuclear intensity ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). The SMAD2 response to ACTIVIN was again transient with a nuclear signal that remained elevated at longer times as demonstrated by our reporter line and by immunofluorescence and western blot analysis of the parental RUES2 line ([Figure 3D--E](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B--C](#fig3s1){ref-type="fig"}). This is consistent with other data based on immunofluorescence ([@bib22]). Although, the adaptive response is somewhat more pronounced in our experimental setup. As with the SMAD1 response, the average SMAD2 response resulted from nearly all cells responding with similar dynamics, which is evident in the shift up and down in the histogram of SMAD2 nuclear intensity ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). The SMAD2 peak response displayed a strong sigmoidal dependence on ACTIVIN concentration ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). However, the post-stimulation baseline, defined as the average SMAD2 nuclear-to-cytoplasmic ratio at T \> 8 hr after ACTIVIN addition, as well as the time scale of the transient response, was not dependent on the ACTIVIN dose above 0.5 ng/mL ([Figure 3---figure supplement 1E--F](#fig3s1){ref-type="fig"}). This transient SMAD2 signaling behavior did not result from depletion of ACTIVIN from the medium, as culture medium recovered from cells that were incubated with ACTIVIN for 12 hr, still induced a SMAD2 response when presented to unstimulated cells ([Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}). SMAD4 followed the dynamics of the relevant R-SMADs following presentation of BMP4 or ACTIVIN ([Figure 3F--G](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1H](#fig3s1){ref-type="fig"}). The stable and adaptive responses of SMAD4 to BMP and ACTIVIN, respectively, is consistent with recent experiments that also utilized this reporter line ([@bib36]; [@bib22]). Thus, in response to their activating ligands, the two branches of the TGFβ pathway display distinct dynamics of signal transduction for both the R-SMAD and the co-SMAD. This also demonstrates that modifying signals do not influence the dynamics of the response at the edge of the micropatterned colonies.

![BMP and ACTIVIN elicit different single-cell SMAD response dynamics.\
(**A**) Schematic outlining the single-cell experimental protocol. (**B**) RFP-SMAD1 response in single cells to BMP4 (5 ng/mL, added at T = 0 hr). (**C**) Quantification of the RFP-SMAD1 nuclear signal as a function of time and BMP4 concentration. Images were acquired every 10 min. Solid lines represent the average response at each time point (n \> 200 cells per time point). Dashed lines represent the population standard deviation for -- BMP4 (light red) and BMP4 (5 ng/mL, dark red) conditions. Similar results were obtained in two independent experiments. (**D**) mCitrine-SMAD2 response in single cells to ACTIVIN (10 ng/mL, added at T = 0 hr). (**E**) Quantification of the mCitrine-SMAD2 nuclear-to-cytoplasmic ratio as a function of time and ACTIVIN concentration. Images were acquired every 10 min. Solid lines represent the average response at each time point (n \> 200 cells per time point). Dashed lines represent the population standard deviation for --ACTIVIN (lightest green) and ACTIVIN (10 ng/mL, darkest green) conditions. Data were collectively obtained from three independent experiments. (**F**) GFP-SMAD4 response in single cells to ACTIVIN (10 ng/mL) or BMP4 (10 ng/mL) or cells that were left untreated (**E7**). Ligands were added at T = 0 hr. (**G**) Quantification of the GFP-SMAD4 nuclear-to-cytoplasmic ratio as a function of time in E7 (blue), E7 +BMP4 (10 ng/mL, red), or E7 +ACTIVIN (10 ng/mL, green). Images were acquired every 10 min. Solid lines represent the average response at each time point (n \> 200 cells per time point). Similar results were obtained in two independent experiments. Scale bars, 25 µm.](elife-38279-fig3){#fig3}

ACTIVIN elicits a transient and stable transcriptional response {#s2-4}
---------------------------------------------------------------

We have previously shown that BMP4 signaling induces a sustained transcriptional response leading to gastruloid differentiation ([@bib57]; [@bib17]). This is consistent with the stable nature of SMAD1 signaling presented above. The adaptive behavior of SMAD2 signaling prompted us to ask whether the short SMAD2 signaling peak was sufficient to elicit a transcriptional response and fate changes in RUES2 cells exposed to ACTIVIN. RNA-seq analysis was performed on dissociated cells cultured in E7 and E7 +ACTIVIN at 1, 2.5, 4, 8 and 12 hr following stimulation. 3529 genes showed a change in expression level of at least two-fold during the experimental time course. They fell into three distinct groups. The first, which consisted of the majority of transcripts (2,956), peaked at 2.5 hr and declined at later time points ([Figure 4A](#fig4){ref-type="fig"}, magenta box). This group matched the timing of the transient SMAD2 response and it included key regulators of mesendodermal differentiation, such as EOMES, HHEX, GATA2, and GATA3 ([Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}) ([@bib52]; [@bib29]). The second group, which consisted of 452 transcripts, showed stable induction ([Figure 4A](#fig4){ref-type="fig"}, orange box). This group included genes expressed during pluripotency, such as NANOG, NODAL, LEFTY1, LEFTY2 and SMAD7 ([Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}) ([@bib42]). Finally, the third group, which consisted of 121 transcripts, represented genes that were stably or transiently down regulated upon ACTIVIN presentation and included genes that are involved in signaling pathways not previously associated with pluripotency or differentiation, such as insulin signaling and cAMP response ([Figure 4A](#fig4){ref-type="fig"}, gray box and [Figure 4---source data 3](#fig4sdata3){ref-type="supplementary-material"}). These results suggest that cells transiently activate differentiation in response to ACTIVIN.

![ACTIVIN/SMAD2 signaling results in stable and transient transcriptional responses.\
(**A**) Hierarchical clustering of RNA-seq time course data for genes showing a fold-change \>2 in response to ACTIVIN (10 ng/mL) relative to the pre-stimulus level (T = 0 hr). The gene z-score at each time point was calculated by subtracting the average and dividing by the standard deviation of the normalized read counts across all time points. (**B--C**) RT-PCR analysis of (**B**) pluripotency- and (**C**) mesendoderm-associated genes following presentation of ACTIVIN (10 ng/mL) in the parental RUES2 line (black bars) and the RUES2-SMAD3^-/-^ lines (gray and white bars). An additional sample was collected that was left untreated for the 12 hr time course (untr). Expression in each sample was normalized to GAPDH and then to the pre-stimulus level (T = 0 hr). Data represents the mean ±S.D. for n = 3 technical replicates. Similar results were obtained in three independent experiments using the parental RUES2 line.\
10.7554/eLife.38279.015Figure 4---source data 1.Hierarchical clustering group one genes (z-score).\
10.7554/eLife.38279.016Figure 4---source data 2.Hierarchical clustering group two genes (z-score).\
10.7554/eLife.38279.017Figure 4---source data 3.Hierarchical clustering group three genes (z-score).\
10.7554/eLife.38279.018Figure 4---source data 4.Motif enrichment analysis for gene groups 1--3.\
10.7554/eLife.38279.019Figure 4---source data 5.Gene enrichment analysis for gene groups 1--3.\
10.7554/eLife.38279.020Figure 4---source data 6.Overlapping genes obtained from gene enrichment analysis.](elife-38279-fig4){#fig4}

Examination of the signaling hierarchy involved in gastruloid self-organization revealed the presence of feedback loops at all three levels. ACTIVIN induced the expression of its own ligands and inhibitors, as well as those of the BMP and WNT pathway ([Figure 4---source data 1--2](#fig4sdata1){ref-type="supplementary-material"}). However, despite the induction of the expression of the ligands and inhibitors, the overall threshold of signaling was not sufficient to induce and maintain mesendodermal fates from either the BMP or the WNT pathway.

We took two additional approaches to evaluate the transient and stable transcriptional responses following ACTIVIN treatment. First, we performed motif enrichment analysis on our gene groups. We selected 10 transcription factors that regulate primitive streak and mesendodermal differentiation: MIXL1, LEF1, BRACHYURY (BRA), GATA6, FOXH1, FOXA1, FOXA2, GOOSECOID (GSC), SOX17, and EOMES, and asked if their binding sites are enriched in the promoter region of the genes belonging to each of the dynamic groups. In support of our hypothesis, the motifs were significantly enriched only in the transiently expressed genes of group one and not within group 2 or 3 ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"} and [Figure 4---source data 4](#fig4sdata4){ref-type="supplementary-material"}). This suggests that the gene regulatory network activated during the peak of SMAD2 signaling is associated with mesendodermal differentiation. We additionally compared our gene groups with tissue specific genes identified in isolated endoderm, mesoderm, and ectoderm/epiblast tissue from E7.5 mouse embryos ([@bib31]). Although all groups contained some significant enrichment of genes from one or more of the mouse germ layers, group one displayed the most significant enrichment of endodermal genes ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"} and [Figure 4---source data 5](#fig4sdata5){ref-type="supplementary-material"}). Overall our data demonstrate that during the peak of SMAD2 nuclear accumulation, hESCs are *en route* for differentiation. However, the mesendodermal differentiation program is not maintained and cells return to pluripotency.

SMAD3 is dispensable for the response of the adaptive and stable gene classes to ACTIVIN {#s2-5}
----------------------------------------------------------------------------------------

In the mouse embryo, SMAD3 is dispensable for early development as demonstrated by the fact that SMAD3 knockout mice make it to adulthood ([@bib63]; [@bib60]; [@bib13]). In the absence of SMAD2 in the epiblast, SMAD3 can mediate some mesoderm induction during gastrulation. However, more anterior mesendodermal lineages are completely eliminated and the embryos fail at gastrulation suggesting a critical role for SMAD2 in this process ([@bib54]; [@bib15]). In order to decipher whether the transient SMAD2 response is sufficient to drive the transcriptional program downstream of ACTIVIN presentation in hESCs, we generated two independent RUES2 SMAD3 knockout lines (RUES2-SMAD3^-/-^) using CRISPR-Cas9 mediated genome editing ([Figure 4---figure supplement 2A--B](#fig4s2){ref-type="fig"}). These lines maintained expression of pluripotency markers NANOG, OCT4, and SOX2, which is consistent with the previous finding that SMAD2, but not SMAD3, regulates NANOG expression to promote pluripotency in hESCs and mouse epiblast stem cells ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}) ([@bib40]). In response to ACTIVIN, RUES2-SMAD3^-/-^ cells displayed a transcriptional response identical to the parental RUES2 line for both pluripotency- and mesendoderm-associated ACTIVIN target genes ([Figure 4B--C](#fig4){ref-type="fig"}). Although our results cannot rule out possible redundancy between SMAD2 and SMAD3, we conclude that SMAD3 is not required for maintenance of pluripotency or the transcriptional response dynamics following ACTIVIN presentation.

Long-term, elevated SMAD2 baseline maintains pluripotency {#s2-6}
---------------------------------------------------------

We have shown that SMAD2 nuclear levels are transient following a step input of ACTIVIN, with a long-term baseline that remains elevated relative to the pre-stimulus level. We next asked if the increase in the SMAD2 baseline after the peak response is required for the maintenance of pluripotency. In order to address this question, RUES2-mCit-SMAD2 cells were treated with SB in order to inhibit ACTIVIN signaling, 8 hr after stimulation, and analyzed for their ability to maintain pluripotency. SB treatment led to a decrease in SMAD2 nuclear-to-cytoplasmic levels back to the unstimulated baseline ([Figure 5A](#fig5){ref-type="fig"}). As observed previously, presentation of SB led to a loss of pluripotency, as indicated by the loss of NANOG expression in RUES2-mCit-SMAD2 ([Figure 5B](#fig5){ref-type="fig"}) ([@bib24]; [@bib53]; [@bib59]). Analysis of the parental RUES2 line confirmed the loss of pluripotency under the same experimental conditions ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). We conclude that the elevated baseline at the tail of the SMAD2 response is ligand dependent and responsible for maintaining the pluripotency program long-term.

![Long-term, elevated SMAD2 baseline maintains pluripotency.\
(**A**) Quantification of the mCitrine-SMAD2 nuclear-to-cytoplasmic ratio following treatment with ACTIVIN (10 ng/mL added at T = 0 hr, solid green line). Following the transient SMAD2 response, SB (10 µM) was added to one of the samples (dotted green line, added at T = 8 hr). A third sample was left untreated in E7 (--ACTIVIN) for the duration of the experiment (solid black line). Images were acquired every 10 min. Lines represent the average response at each time point (n \> 200 cells per time point). Similar results were obtained in two independent experiments. (**B**) The samples in A were fixed 24 hr after ACTIVIN addition and analyzed for NANOG expression by immunofluorescence (IF). Histograms show the nuclear IF signal quantified in single cells (n \> 5,000 cells per condition). Scale bar, 50 µM. (**C--D**) RUES2 cells were cultured in E7 with different levels of Activin (0, 1, 10, 100 ng/mL) or SB (10 µM) for 2 days. Cells were fixed and analyzed by immunofluorescence (IF). (**C**) Images: NANOG (red), OCT4 (green), SOX2 (cyan), DAPI (gray). Scale bar, 50 µM. (**D**) Histograms showing the nuclear IF signal quantified in single cells (n \> 5,000 cells per condition). Similar results to those shown in C and D were obtained in two independent experiments in RUES2 and in an additional hESC line, RUES1 (see [Figure 5---figure supplement 1B--C](#fig5s1){ref-type="fig"}). (**E**) Kolmogorov-Smirnov (KS) distance of the cumulative probability distribution (CDF) of each marker to the reference CDF (1 ng/mL ACTIVIN condition) for independent experiments in RUES2 and in RUES1. n.s., not significant, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001, ANOVA.](elife-38279-fig5){#fig5}

The fact that the SMAD2 post-stimulation baseline is the same regardless of ACTIVIN concentration above 0.5 ng/mL, suggests that pluripotency is insensitive to graded ligand levels above this threshold ([Figure 3E](#fig3){ref-type="fig"}). To test this hypothesis, we treated single cells with different levels of ACTIVIN and compared the expression of NANOG, OCT4, and SOX2 after 2 days of stimulation. Expression of all three markers was similar at three different concentrations of added ACTIVIN (1, 10, and 100 ng/mL) and expression of NANOG and OCT4 was elevated relative to the --ACTIVIN condition ([Figure 5C--D](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}; results from additional hESC line RUES1 shown in [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). To test for zero ACTIVIN/SMAD2 input we presented SB for the same amount of time. Pluripotency was not maintained under these conditions as demonstrated by down-regulation of NANOG and OCT4 below the --ACTIVIN condition ([Figure 5C--D](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1B--C](#fig5s1){ref-type="fig"}). Toxicity as a result of SB treatment or increased ACTIVIN levels was not observed ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). This confirms the insensitivity of the pluripotent state to graded ACTIVIN. Even at the highest ligand concentrations pluripotency was maintained and no differentiation was observed.

In order to compare immunofluorescence data across biological replicates, which may differ in absolute intensity values, we computed the Kolmogorov-Smirnov (KS) distance between each marker's cumulative distribution function (CDF) measured under different conditions to a reference CDF, in this case the CDF measured under the 1 ng/mL ACTIVIN condition ([Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"}). In biological replicates using RUES2 or RUES1 the distributions of NANOG and OCT levels under the 100 or 10 ng/mL ACTIVIN conditions are reproducibly close to the distributions measured under the 1 ng/mL ACTIVIN condition (small KS distance, [Figure 5E](#fig5){ref-type="fig"}). Whereas the distributions measured under the --ACTIVIN and SB conditions are reproducibly far from the distributions measured under the 1 ng/mL ACTIVIN condition (large KS distance, [Figure 5E](#fig5){ref-type="fig"}). This analysis demonstrates the reproducibility of our findings that the pluripotent state is insensitive to graded ACTIVIN levels.

WNT priming unveils ACTIVIN-dependent mesendoderm differentiation {#s2-7}
-----------------------------------------------------------------

We have demonstrated that ACTIVIN alone cannot drive stable differentiation of human gastruloids. However, WNT can lead to differentiation and self-organization of gastruloids in a SMAD2/3 dependent manner ([@bib32]). Since WNT is operating up-stream of ACTIVIN/NODAL in the proposed signaling hierarchy, we asked whether cells with a history of WNT signaling might respond differently to ACTIVIN treatment. To address this, cells were treated with WNT for 24 hr, washed to remove WNT, and then cultured with or without ACTIVIN for an additional 24 hr ([Figure 6A](#fig6){ref-type="fig"}). Surprisingly, when cells were treated with WNT alone in the absence of ACTIVIN no mesendodermal differentiation was observed and cells remained pluripotent ([Figure 6B--C](#fig6){ref-type="fig"}). However, if the cells were exposed to WNT before ACTIVIN stimulation mesendodermal fates were robustly induced ([Figure 6D--E](#fig6){ref-type="fig"}). KS distance analysis using the pluripotency condition (-/ACT) as the reference condition demonstrated the reproducibility of these observations in RUES2 and RUES1 ([Figure 6F--G](#fig6){ref-type="fig"}). Following WNT and ACTIVIN treatment, mesendoderm marker expression was also observed in the RUES2-SMAD3^-/-^ line, suggesting that SMAD3 is not necessary for ACTIVIN-dependent mesendoderm induction ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Differentiation was ACTIVIN concentration dependent, as demonstrated by the induction of BRA at low ACTIVIN and the induction of BRA, EOMES and GSC at high ACTIVIN concentrations ([Figure 6---figure supplement 1B--D](#fig6s1){ref-type="fig"}). Therefore, following WNT priming ACTIVIN functions as a morphogen to pattern mesendodermal fates and SMAD3 is again dispensable for this process.

![WNT priming unveils ACTIVIN-dependent mesendoderm differentiation.\
(**A**) Schematic outlining the 2 day experimental protocol. (**B--C**) Cells were cultured for one day with or without WNT3A (100 ng/mL, top bar). On the second day they were washed to remove WNT and treated with or without ACTIVIN (10 ng/mL, bottom bar). After the second day cells were fixed and analyzed by immunofluorescence (IF). (**B**) Images: NANOG (red), OCT4 (green), SOX2 (cyan), DAPI (gray). Scale bar, 50 µM. (**C**) Histograms showing the nuclear IF signal quantified in single cells (n \> 5,000 cells per condition). (**D--E**) Cells were cultured for one day with or without WNT3A (100 ng/mL, top bar). On the second day they were washed to remove WNT and treated with or without ACTIVIN (10 ng/mL, bottom bar). After the second day cells were fixed and analyzed by immunofluorescence (IF). (**D**) Images: BRA (red), EOMES (green), GSC (cyan), DAPI (gray). Scale bar, 50 µM. (**E**) Histograms showing the nuclear IF signal quantified in single cells (n \> 5,000 cells per condition). (**F--G**) Kolmogorov-Smirnov (KS) distance of the cumulative probability distribution (CDF) of each marker to the reference CDF (-/ACT) for independent experiments in RUES2 and in RUES1 for the (**F**) pluripotency and (**G**) mesendoderm marker sets. n.s. (or comparison not shown), not significant, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, ANOVA.](elife-38279-fig6){#fig6}

WNT memory stabilizes the mesendodermal transcriptional response to ACTIVIN {#s2-8}
---------------------------------------------------------------------------

In order to address the mechanism of WNT priming, we first asked whether the transcriptional effector of canonical WNT signaling, β-catenin, is involved in this process. We therefore treated cells with the small molecule inhibitor endo-IWR-1, which blocks β-catenin function through stabilization of its destruction complex. endo-IWR-1 was added with WNT on day one and again with ACTIVIN on day 2. In the presence of endo-IWR-1 mesendoderm maker expression was eliminated and pluripotency marker expression was maintained, indicating a requirement for β-catenin in the differentiation process ([Figure 7A](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). We then asked if endogenous WNT, induced by a possible positive feedback loop, is required for stable induction of mesendoderm, particularly during the ACTIVIN treatment phase when exogenous WNT has been removed. To address this we blocked endogenous WNT secretion using the small molecule inhibitor IWP-2, which was added with WNT on day one and again with ACTIVIN on day 2. We find that addition of IWP-2 does not affect ACTIVIN-dependent mesendoderm differentiation and loss of pluripotency ([Figure 7A](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). However, IWP-2 at the same concentration does block WNT-dependent mesendoderm differentiation downstream of BMP4 ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}) ([@bib32]). Toxicity as a result of either endo-IWR-1 or IWP-2 treatment was not observed ([Figure 7B](#fig7){ref-type="fig"}). Together, these results demonstrate the presence of an unexpected WNT signaling memory in cells that is mediated via β-catenin and is established prior to and is required for the morphogen activity of ACTIVIN.

![WNT priming stabilizes mesendoderm gene transcription without changing SMAD2 and SMAD4 response dynamics.\
(**A**) Cells were cultured for one day with WNT3A (100 ng/mL). On the second day they were washed to remove WNT and treated with ACTIVIN (10 ng/mL). In order to block WNT signaling through β-catenin cells were treated with endo-IWR-1 (1 µM), which was added with WNT on day one and again with ACTIVIN on day 2. In order to block WNT secretion, cells were similarly treated with IWP-2 (1 µM). After the second day cells were fixed and analyzed by immunofluorescence (IF). Histograms show the nuclear IF signal quantified in single cells (n \> 5,000 cells per condition). Cells cultured without WNT, corresponding to the pluripotency condition (-/ACT, open circles), represent background signal levels. (**B**) Quantification of the final cell density in the experiment shown in A and in additional replicates. There is no significant difference between the densities under different conditions (ANOVA). (**C**) mCitrine-SMAD2 (left) and GFP-SMAD4 (right) response in single cells to ACTIVIN (10 ng/mL) with or without WNT priming (black solid and dashed lines, respectively). ACTIVIN was added at T = 0 hr, which corresponds to 24 hr of WNT stimulation. WNT was removed by washing prior to the addition of ACTIVIN. Images were acquired every 10 min. The black solid and dashed lines represent the average response at each time point and the gray dashed lines represent the population standard deviation of the SMAD2 response without WNT priming (n \> 200 cells per time point). Similar results were obtained in two independent experiments. (**D**) Transcriptional response of mesendoderm genes to ACTIVIN with or without WNT priming. An additional sample was collected that was treated with WNT and left untreated with ACTIVIN (-ACT). Expression in each sample was normalized to GAPDH and then to the level prior to ACTIVIN addition (T = 0 hr). Data represents the mean ±S.D. for n = 3 technical replicates. n.d., not detected. Similar results were obtained in two independent experiments. (**E**) Model for WNT priming as a requirement for ACTIVIN to function as a morphogen. Following implantation ACTIVIN functions in a dose-independent manner to maintain pluripotency of the epiblast. At the onset of gastrulation, WNT signaling primes cells respond to graded ACTIVIN/SMAD2 signaling, which leads to the anterior-posterior patterning of cells emerging from the primitive streak (PS).](elife-38279-fig7){#fig7}

Since we have shown that the SMAD response dynamics can be stable or transient depending on the branch being activated, we next asked if WNT memory affects the dynamics of SMAD2 signal transduction. The transient response of SMAD2 and SMAD4 and the elevation in the baseline post-stimulation was the same whether or not cells were previously exposed to WNT ([Figure 7C](#fig7){ref-type="fig"}). However, transcription of mesendodermal genes was stabilized in response to ACTIVIN following WNT priming ([Figure 7D](#fig7){ref-type="fig"}). As in the case of pluripotency, stable mesendodermal fate acquisition required on-going SMAD2 signaling in the elevated baseline as treatment with SB, 8 hr after ACTIVIN stimulation, eliminated mesendodermal differentiation at 24 hr after ACTIVIN ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}). In contrast, and further arguing for a mechanism of WNT priming that is temporally up-stream of ACTIVIN, addition of SB during WNT priming did not block mesendoderm differentiation ([Figure 7---figure supplement 1E](#fig7s1){ref-type="fig"}). Overall, we conclude that cells maintain a memory of WNT exposure, which makes them competent to differentiate in response to ACTIVIN ([Figure 7E](#fig7){ref-type="fig"}).

Discussion {#s3}
==========

Following the tradition of experimental embryology, during the late 1960 s, Nieuwkoop began a series of explant and transplant experiments in the amphibian blastula that ultimately led to the discovery of ACTIVIN as a mesoderm inducer in the 1980 s ([@bib37]; [@bib33]). When presented to isolated animal cap explants that normally give rise only to ectoderm, ACTIVIN was sufficient to induce different types of mesendodermal cells based on its concentration, and was thus qualified in principle as a morphogen ([@bib20]; [@bib58]). When the ACTIVIN receptors and the SMAD pathways were characterized in 1990 s, it was shown that micro-injection of different amounts of synthetic mRNAs encoding SMAD2 into *Xenopus* animal caps, also recapitulates the mesendodermal-inducing effects of A ACTIVIN morphogen presentation, independently confirming that the activation of different thresholds of the pathway was sufficient for mesoderm induction ([@bib45]). Inhibition of the pathway by microinjection of a dominant negative type II ACTIVIN receptor into *Xenopus* blastula led to complete loss of mesendodermal derivatives, demonstrating that ACTIVIN/SMAD2 signaling was necessary for mesoderm induction in the amphibian embryo ([@bib23]).

Loss-of-function analysis in the mouse later confirmed the frog conclusions about the pathway as SMAD2/3 double knockout mice failed to properly induce mesendoderm and gastrulate ([@bib15]). However another TGFβ ligand, NODAL, rather than ACTIVIN was shown to be the inducer in the mammalian embryo ([@bib10]). Elegant genetic experiments also performed in the mouse placed NODAL signaling in a positive feedback loop that drives gastrulation. The loop is initiated when NODAL signaling induces BMP4 expression in the extra-embryonic ectoderm. BMP signaling subsequently induces WNT3 expression, which in turn induces high levels of NODAL in the proximal-posterior part of the embryo, which marks the site of primitive streak initiation ([@bib2]).

Using live reporters of SMAD1, SMAD2 and SMAD4, we find that BMP/SMAD1 signaling is stable, ACTIVIN/SMAD2 signaling is transient (or adaptive), and that co-SMAD4 follows the dynamics of the receptor-associated SMADs. In response to ACTIVIN, hESCs transiently induce mesendodermal gene expression, without generating mesendodermal fates, and the cells return to the state of pluripotency. However, the expression of ACTIVIN/NODAL inhibitors remained elevated and plausibly buffer the additional ACTIVIN, as expected from prior theory ([@bib18]). Pre-presentation of WNT, however, stabilizes transcription and fate acquisition without modifying SMAD2 dynamics. Thus, a transient signaling response is compatible with a stable change in cell fate, as shown previously in a murine myoblast cell line ([@bib49]). Both pluripotency maintenance and mesendodermal fate acquisition are not affected by the loss of SMAD3. Our data provide evidence for a previously undetected level of signal integration that implies the presence of a cellular memory. This memory operates not at the level of the SMAD2 signaling dynamics but by some other means to change the response of the cells to ACTIVIN. It is tempting to speculate that it might be mediated through epigenetic mechanisms, in a manner similar to what has been described in *Xenopus* experiments where β-catenin recruits PrMT2 to induce dorsal fates ([@bib5]).

The ACTIVIN/SMAD2 pathway has been shown to be necessary for maintenance of pluripotency, but not sufficient to induce mesendoderm in hESCs, except when influenced by modifiers of other signaling pathways ([@bib12]; [@bib34]; [@bib46]; [@bib19]). Our study shows that mere pre-treatment of hESCs with WNT, endows them with a memory that enables a graded response to subsequently applied ACTIVIN; simultaneous exposure to WNT and ACTIVIN is not required. Furthermore, the WNT treatment alone is not sufficient to elicit a stable fate change since in minimal media, without ACTIVIN, the cells revert to pluripotency. The ability of embryonic cells to record WNT signals may be a broadly conserved and fundamental aspect of animal development, as shown by elegant experiments in *Drosophilia* where the authors demonstrate a morphogen effect for Dpp (a BMP homologue) after cells have lost contact with the source of WNT ([@bib1]).

In the context of vertebrate development, our findings force the reevaluation of the traditional literature regarding the sufficiency of the ACTIVIN/SMAD2 pathway for mesendodermal induction and patterning. A review of the evidence in model systems for the ACTIVIN/NODAL mediated morphogen effect reveals that in all the experimental settings, at least some of the cells were either still under the influence, or had been previously exposed to WNT signaling before or during ACTIVIN/NODAL signaling. For example, cells of the *Xenopus* animal cap derived from the blastula stage embryo have been under maternal WNT influence as early as the two-cell stage, hours before ACTIVIN is presented to the explants. This influence is the consequence of cortical rotation that occurs after sperm entry, and activates the WNT pathway on the dorsal side of the embryo, as evidenced by the dorsal-specific nuclear localization of β-catenin ([@bib44]; [@bib28]; [@bib39]). It is clear from the asymmetric elongation of the animal cap explants in response to ACTIVIN that the prior WNT exposure sets up a dorsal-ventral pre-pattern that affects the response. It is also clear that the dorsal and ventral regions of the animal cap when separated respond differently to ACTIVIN ([@bib48]; [@bib6]). Although some mesoderm is induced in the ventral caps, only cells of the dorsal cap that have seen WNT signals undergo ACTIVIN-mediated induction of GSC + mesendoderm. These experiments demonstrate that both pathways are required for complete mesendodermal patterning without explicitly distinguishing their temporal relationship.

Our study revises this point of view by bringing a temporal order. We suggest that only cells endowed with a WNT memory can respond to ACTIVIN to specify the full range of mesendodermal fates. Even in the extensively studied *Xenopus* embryo, it is still debated whether in the late blastula stage marginal zone, prior to the onset of gastrulation, an ACTIVIN/NODAL gradient already defines the medial to lateral mesendodermal fates or whether there is simply a bipartite division into dorsal organizer and ventral mesoderm ([@bib21]; [@bib47]). This debate also translates into whether ACTIVIN/NODAL is sufficient to pre-pattern the mesendoderm or whether complete patterning requires prior WNT exposure present only in the dorsal part of the embryo. Controversies persist, since the embryo is rapidly developing, there are no live reporters of signaling, and fates are often assayed in early gastrulation rather than in the late blastula. In the mouse the earliest manifestation of the streak is the proximal-posterior expression of WNT, which extends distally. By mid-streak stage, NODAL signaling is highest in the Node ([@bib51]). Thus, cells that leave the streak at various proximal-distal positions and NODAL levels, manifestly have been exposed to WNT first ([@bib50]). This interpretation, however, does not eliminate the co-requirement for ACTIVIN and WNT, but rather suggests that instructive WNT, required for mesendodermal differentiation, occurs temporally up-stream of ACTIVIN/SMAD2 signaling.

In conclusion, a cellular memory of WNT signaling, endows embryonic cells, including hESCs, with the competence to maintain ACTIVIN/SMAD2-mediated mesendodermal fate specification and patterning.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\           Designation                 Source or reference                                                    Identifiers                                                                               Additional information
  (species) or resource                                                                                                                                                                                                
  ----------------------- --------------------------- ---------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ---------------------------
  Cell line\              RUES2                       US National Institutes of Health, human ESC registry                   human ESC registry no. 0013; RRID:[CVCL_VM29](https://scicrunch.org/resolver/CVCL_VM29)   Human embryonic\
  (*Homo sapiens*, XX)                                                                                                                                                                                                 stem cell line

  Cell line\              RUES2-RFP-SMAD1             this paper                                                                                                                                                       CRISPR/Cas9-modified\
  (*Homo sapiens*, XX)                                                                                                                                                                                                 human embryonic\
                                                                                                                                                                                                                       stem cell line

  Cell line\              RUES2-mCit-SMAD2            this paper                                                                                                                                                       CRISPR/Cas9-modified\
  (*Homo sapiens*, XX)                                                                                                                                                                                                 human embryonic\
                                                                                                                                                                                                                       stem cell line

  Cell line\              RUES2-GFP-SMAD4             PMID: 28760810                                                                                                                                                   CRISPR/Cas9-modified\
  (*Homo sapiens*, XX)                                                                                                                                                                                                 human embryonic\
                                                                                                                                                                                                                       stem cell line

  Cell line\              RUES2-SMAD3-/- clone \#1    this paper                                                                                                                                                       CRISPR/Cas9-modified\
  (*Homo sapiens*, XX)                                                                                                                                                                                                 human embryonic\
                                                                                                                                                                                                                       stem cell line

  Cell line\              RUES2-SMAD3-/- clone \#2    this paper                                                                                                                                                       CRISPR/Cas9-modified\
  (*Homo sapiens*, XX)                                                                                                                                                                                                 human embryonic\
                                                                                                                                                                                                                       stem cell line

  Cell line\              RUES1                       US National Institutes of Health, human ESC registry                   human ESC\                                                                                Human embryonic\
  (*Homo sapiens*, XY)                                                                                                       registry no. 0012;\                                                                       stem cell line
                                                                                                                             RRID:[CVCL_B809](https://scicrunch.org/resolver/CVCL_B809)                                

  Antibody                anti-Brachyury\             R and D Systems                                                        Cat. \#: AF2085;\                                                                         IF (1:300)
                          (goat polyAb)                                                                                      RRID:[AB_2200235](https://scicrunch.org/resolver/AB_2200235)                              

  Antibody                anti-Brachyury\             R and D Systems                                                        Cat. \#: MAB20851                                                                         IF (1:200)
                          (rabbit mAb)                                                                                                                                                                                 

  Antibody                anti-Cdx2\                  Abcam                                                                  Cat. \#: ab15258;\                                                                        IF (1:50)
                          (mouse mAb)                                                                                        RRID:[AB_2077042](https://scicrunch.org/resolver/AB_2077042)                              

  Antibody                anti-Eomes\                 R and D Systems                                                        Cat. \#: MAB6166;\                                                                        IF (1:200)
                          (mouse mAb)                                                                                        RRID:[AB_10919889](https://scicrunch.org/resolver/AB_10919889)                            

  Antibody                anti-Lamin B1\              Proteintech                                                            Cat. \#: 12987--1-AP;\                                                                    WB (1:2000)
                          (rabbit polyAb)                                                                                    RRID:[AB_2136290](https://scicrunch.org/resolver/AB_2136290)                              

  Antibody                anti-Goosecoid\             R and D Systems                                                        Cat. \#: AF4086;\                                                                         IF (1:100)
                          (goat polyAb)                                                                                      RRID:[AB_2114650](https://scicrunch.org/resolver/AB_2114650)                              

  Antibody                anti-Nanog\                 R and D Systems                                                        Cat. \#: AF1997;\                                                                         IF (1:200)
                          (goat polyAb)                                                                                      RRID:[AB_355097](https://scicrunch.org/resolver/AB_355097)                                

  Antibody                anti-Oct3/4\                BD Biosciences                                                         Cat. \#: 611203;\                                                                         IF (1:400)
                          (mouse mAb)                                                                                        RRID:[AB_398737](https://scicrunch.org/resolver/AB_398737)                                

  Antibody                anti-Smad2\                 Cell Signaling                                                         Cat. \#: 3122;\                                                                           IF (1:200),\
                          (rabbit mAb)                                                                                       RRID:[AB_10697649](https://scicrunch.org/resolver/AB_10697649)                            WB (1:1000)

  Antibody                anti-Smad2/3\               BD Biosciences                                                         Cat. \#: 610842;\                                                                         IF (1:100)
                          (mouse mAb)                                                                                        RRID:[AB_398161](https://scicrunch.org/resolver/AB_398161)                                

  Antibody                anti-Sox17\                 R and D Systems                                                        Cat. \#: AF1924;\                                                                         IF (1:200)
                          (goat polyAb)                                                                                      RRID:[AB_355060](https://scicrunch.org/resolver/AB_355060)                                

  Antibody                anti-Sox2\                  Cell Signaling                                                         Cat. \#: 3579;\                                                                           IF (1:200)
                          (rabbit mAb)                                                                                       RRID:[AB_2195767](https://scicrunch.org/resolver/AB_2195767)                              

  Peptide,\               recombinant human/mouse/\   R and D Systems                                                        Cat. \#: 338-AC/CF                                                                        
  recombinant\            rat Activin A                                                                                                                                                                                
  protein                                                                                                                                                                                                              

  Peptide,\               recombinant\                R and D Systems                                                        Cat. \#: 314 BP                                                                           
  recombinant\            human BMP-4                                                                                                                                                                                  
  protein                                                                                                                                                                                                              

  Peptide,\               recombinant\                R and D Systems                                                        Cat. \#: 1324-WN                                                                          
  recombinant\            mouse Wnt-3a                                                                                                                                                                                 
  protein                                                                                                                                                                                                              

  Peptide,\               recombinant\                BioLamina                                                                                                                                                        
  recombinant\            human\                                                                                                                                                                                       
  protein                 Laminin-521                                                                                                                                                                                  

  Chemical\               endo-IWR-1                  Tocris                                                                 Cat. \#: 3532                                                                             
  compound, drug                                                                                                                                                                                                       

  Chemical\               IWP-2                       Stemgent                                                               Cat. \#: 04--0034                                                                         
  compound, drug                                                                                                                                                                                                       

  Chemical\               SB431542                    Stemgent                                                               Cat. \#: 04--0010                                                                         
  compound, drug                                                                                                                                                                                                       

  Chemical\               Y-27632                     Abcam                                                                  Cat. \#: Ab120129                                                                         
  compound, drug                                                                                                                                                                                                       

  Software,\              MATLAB                      MathWorks                                                              RRID:[SCR_001622](https://scicrunch.org/resolver/SCR_001622)                              
  algorithm                                                                                                                                                                                                            

  Software,\              StemCellTracker             <https://github.com/ChristophKirst/StemCellTracker>                                                                                                              Image segmentation\
  algorithm                                                                                                                                                                                                            and signal analysis

  Software,\              R                           <https://www.r-project.org/>                                                                                                                                     
  algorithm                                                                                                                                                                                                            

  Software,\              DESeq2\                     PMID: 25516281                                                                                                                                                   Differential gene\
  algorithm               Bioconductor\                                                                                                                                                                                expression analysis
                          package                                                                                                                                                                                      

  Software,\              PWMEnrich\                  <https://bioconductor.org/packages/release/bioc/html/PWMEnrich.html>                                                                                             Motif enrichment analysis
  algorithm               Bioconductor\                                                                                                                                                                                
                          package                                                                                                                                                                                      

  Software,\              GOseq\                      PMID: 20132535                                                                                                                                                   Statistical analysis\
  algorithm               Bioconductor\                                                                                                                                                                                of over/under\
                          package                                                                                                                                                                                      represented categories

  Software,\              AME                         PMID: 25953851                                                                                                                                                   Motif enrichment\
  algorithm                                                                                                                                                                                                            analysis

  Software,\              Tide                        PMID: 25300484                                                                                                                                                   Sequence trace\
  algorithm                                                                                                                                                                                                            decomposition

  Software,\              Cluster 3.0                 PMID: 14871861                                                                                                                                                   Clustering
  algorithm                                                                                                                                                                                                            

  Software,\              Java TreeView               PMID: 15180930                                                                                                                                                   Data visualization
  algorithm                                                                                                                                                                                                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Human embryonic stem cell culture {#s4-1}
---------------------------------

Experiments were performed with the RUES2 hESC line (XX female; US National Institutes of Health, human ESC registry no. 0013) or CRISPR/Cas9 edited cell lines based on RUES2. Key experiments were repeated with the RUES1 hESC line (XY male; US National Institutes of Health, human ESC registry no. 0012). RUES1 and RUES2 have been authenticated by STR profiling and both tested negative for mycoplasma contamination. hESCs were grown in HUESM medium that was conditioned by mouse embryonic fibroblasts and supplemented with 20 ng/mL bFGF (MEF-CM). Cells were grown on tissue culture dishes (BD Biosciences, San Jose, CA) for maintenance and expansion at 37°C and 5% CO~2~. Dishes were coated overnight at 4°C with Geltrex (Thermo Fisher Scientific, Waltham, MA) diluted 1:40 in DMEM/F12 and then incubated at 37°C for at least 20 min before passaging. Cells were passaged as aggregates using Gentle Cell Dissociation Reagent (STEMCELL Technologies, Vancouver, Canada).

Micropatterned cell culture {#s4-2}
---------------------------

Individual micropatterned coverslips (CYTOO, Grenoble, France) were washed one time with water for 5 min at room temperature (RT) to activate the surface according to the manufacturers recommendation. Coverslips were then coated at 37°C for 2 hr with 20 µg/mL Laminin-521 (BioLamina, Sundbyberg, Sweden) in 0.5 mL PBS + Mg/+Ca. The laminin was then removed by serial dilutions without allowing the coverslip to dry (1:4 dilution in PBS --Mg/--Ca, six times). Chips were seeded immediately or stored overnight at 4°C in 2 mL PBS --/-- and seeded on the following day.

Cell seeding was performed as follows. Cells growing in MEF-CM were washed once with PBS +/+ and dissociated to single cells with Accutase (STEMCELL Technologies). Cells were centrifuged and 600,000 cells were resuspended in 2 mL of MEF-CM supplemented with 10 µM Rock-inhibitor (Y-27632, Abcam, Cambridge, MA). The cell suspension was then placed over the coverslip in a 35 mm tissue culture dish. The sample was left unperturbed for 10 min at RT in order to achieve homogeneous seeding of the cells throughout the chip before being moved to the incubator. After 2 hr, the medium was replaced with MEF-CM without Rock-inhibitor and the cells were incubated overnight. On the following day, the medium was changed to MEF-CM with additional ligands, BMP4, WNT3A, or ACTIVIN A (R and D Systems, Minneapolis, MN) with or without 10 µM SB431542 (Stemgent, Lexington, MA). We stimulated cells with ACTIVIN A rather than NODAL, because although both ligands differentiate hESCs towards the mesendoderm lineage, NODAL requires much higher concentrations to be effective ([@bib34]). For experiments in TeSR-E7 (STEMCELL Technologies), cells were moved to E7 medium the day after seeding and incubated for an additional 24 hr before adding ligands. Live imaging was carried out in E7 imaging medium, which was prepared with FluoroBrite DMEM (Thermo Fisher Scientific) according the published protocol for E8 ([@bib4]).

Single-cell culture {#s4-3}
-------------------

Optical-quality plastic tissue culture dishes (ibidi, Martinsried, Germany) were coated with 10 µg/mL Laminin-521 in PBS +/+ for 2 hr at 37°C or overnight at 4°C. Single cells were collected as described for micropatterned cell culture and dishes were seeded with 50,000 single cells resuspended in 2 mL E7 supplemented with 10 µM Rock-inhibitor. The samples were incubated overnight. On the following day, the medium was changed to E7 supplemented with 10 µM Rock-inhibitor and ligands or small molecules. For the 2 day protocol in which cells were switched from E7 ±100 ng/mL WNT3A to E7 ±10 ng/mL ACTIVIN A, the samples were washed with PBS +/+ before adding fresh medium. Live imaging was carried out in E7 imaging medium. Small molecules were used at the following concentrations and were replaced every 24 hr: 10 µM SB431542 (Stemgent), 1 µM IWP-2 (Stemgent), and 1 µM endo-IWR-1 (Tocris).

Immunofluorescence and western blotting {#s4-4}
---------------------------------------

Cells on dishes or coverslips were rinsed once with PBS --/--, fixed with 4% paraformaldehyde (Alfa Aesar, Thermo Fisher Scientific, Tewksbury, MA) for 20 min at RT, and then rinsed twice and stored in PBS --/--. Cells were blocked and permeabilized with blocking buffer (2% bovine serum albumin and 0.1% Triton X-100 in PBS --/--) for 30 min at RT. Cells were incubated with primary antibodies in blocking buffer overnight at 4°C and then washed three times with 0.1% Tween-20 in PBS --/-- (PBST). Cells were incubated with secondary antibodies (diluted 1:1000): Alexa Fluor 488, 555, or 647-conjugated from (Invitrogen Molecular Probes, Thermo Fisher Scientific) and DAPI nuclear stain (1:10,000 dilution) in blocking buffer for 30 min at RT, and then washed twice with PBST and once with PBS --/--. Dishes were stored and imaged in PBS --/--. Coverslips were mounted on slides using Fluoromount-G mounting medium (SouthernBiotech, Birmingham, AL).

Western blotting was performed using standard techniques. The nuclear fractions presented in [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"} were obtained using the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific) and following the manufacturers protocol. Following SDS-PAGE and Western transfer, membranes were stained with anti-Smad2 Rabbit mAb (Cell Signaling Technology, Danvers, MA) at 1:1000 dilution. Membranes were stripped for 15 min at RT using Restore PLUS Western Blot Stripping Buffer (ThermoFisher Scientific) and re-stained with anti-Lamin B1 Rabbit polyAb (Proteintech, Rosemont, IL) at 1:2000 dilution.

Imaging {#s4-5}
-------

Wide-field images of fixed samples were acquired on an Olympus IX-70 inverted microscope with a 10x/0.4 numerical aperture objective lens. Tiled image acquisition was used to acquire images of large areas of dishes or coverslips in four channels corresponding to DAPI and Alexa Fluor 488, 555, and 647. Live imaging was performed on a spinning disk confocal microscope equipped with 405-, 488-, and 561 nm lasers and an environmental chamber (CellVoyager CV1000, Yokogawa). Images were acquired every 10 min with a 20x/0.75 numerical aperture objective lens. The cells were maintained at 37°C and 5% CO~2~ during live imaging.

Generation of SMAD1 and SMAD2 reporter cell lines {#s4-6}
-------------------------------------------------

For the tagRFP-SMAD1 reporter cells, CRISPR/Cas9 mediated genome engineering was used to fuse a cassette containing a blasticidin resistance gene (BsdR), a T2A self-cleaving peptide, and a tagRFP fluorescent protein onto the N-terminus of SMAD1, so that the locus produces both a tagRFP-SMAD1 fusion protein together with BsdR. Similarly, for the mCitrine-SMAD2 reporter line, CRISPR/Cas9 was used to fuse a cassette containing a puromycin resistance gene (PuroR), a T2A self-cleaving peptide, and an mCitrine fluorescent protein onto the N-terminus of SMAD2, so that the locus produces both an mCitrine-SMAD2 fusion protein together with PuroR.

RUES2 hESCs were nucleofected with a pX335 plasmid ([@bib9]) that co-expresses the nickase version of Cas9 and the specific sgRNA of interest (protospacer sequences: 5'-GCAGCACTAGTTATACTCCT-3' for SMAD1 and 5'-GGACGACATGTTCTTACCAA-3' for SMAD2), as well as the appropriate homology donor plasmid. Nucleofection was carried out using the Cell Line Nucelofector Kit L (Lonza, Walkersville, MD) and the B-016 setting of a Nucleofector II instrument. Nucleofected cells were plated into MEF-CM supplemented with 10 µM Rock-inhibitor. After 4 days, blasticidin or puromycin was added for 7 days to select for cells that had been targeted. Cells that survived selection were passaged as single cells using Accutase, plated in MEF-CM supplemented with 10 µM Rock-inhibitor, and allowed to grow into colonies. Colonies arising from a single cell were handpicked, expanded, and screened for correct targeting by PCR amplification of the genomic region and Sanger sequencing. Correctly targeted clones were subsequently transfected with ePiggyBac plasmids containing either H2B-mCitrine or H2B-mCherry cassettes to enable nuclear labeling for cell tracking ([@bib27]). Individual clones were again isolated and controlled for normal karyotype (G-banding) and pluripotency maintenance.

Generation of SMAD3 knockout cell lines {#s4-7}
---------------------------------------

RUES2 hESCs were nucleofected with a pX330 plasmid ([@bib9]) that co-expressed the wild-type version of Cas9 and one of two sgRNAs targeting SMAD3 (protospacer sequences: 5'-CCACCAGATGAACCACAGCA-3' for sgRNA \#1 and 5'-TTATTATGTGCTGGGGACAT-3' for sgRNA \#2). The sgRNAs were designed to target the first or second coding exon shared by all SMAD3 isoforms, a strategy that was successfully used to knockout SMAD3 in human primary cell lines ([@bib55]). Two different sgRNAs were used to control for off-target effects. We modified the pX330 plasmid to also express a puromycin-2A-EGFP cassette to enrich for cells that had been successfully nucleofected. Nucleofection was carried out as described above and cells were plated in MEF-CM supplemented with 10 µM Rock-inhibitor. On the following day puromycin was added for 24 hr. Cells that survived selection were allowed to recover for several days. Cells were then passaged as single cells using Accutase, plated in MEF-CM supplemented with 10 µM Rock-inhibitor, and allowed to grow into colonies. Colonies arising from a single cell were handpicked, expanded, and screened for correct targeting by PCR amplification of the genomic region and Sanger sequencing. The resulting chromatograms were decomposed using the Tide web-based tool ([@bib7]).

RT-PCR {#s4-8}
------

RUES2 cells were seeded in 6-well plates (1,00,000 single cells per well) in E7 medium supplemented with 10 µM Rock-inhibitor and incubated overnight. On the following day the medium was changed to E7 supplemented with 10 µM Rock-inhibitor with or without 10 ng/mL ACTIVIN A. Samples (three pooled-wells) were collected in 1 mL Trizol at 0, 2.5, 4, 6 and 12 hr. The 2 day protocol was carried out similarly: the medium was changed on the day after seeding to E7 supplemented with 10 µM Rock-inhibitor with or without 100 ng/mL WNT3A. On the second day following seeding the wells were washed once with PBS and the media was changed to E7 supplemented with 10 µM Rock-inhibitor with or without 10 ng/mL ACTIVIN A. Samples were collected in 1 mL Trizol before the addition of WNT3A, after WNT3A treatment (referred to as 0 hr), and at 2.5, 4, 8, and 12 hr after the addition of ACTIVIN A. Total cellular RNA for each sample was extracted using the RNeasy Mini Kit (QIAGEN, Germantown, MD) and cDNA was synthesized using the Transcriptor First Strand cDNA Synthesis Kit (Roche). RT-PCR for selected genes was performed on three technical replicates using the LightCycler 480 SYBR Green I Master mix in a LightCycler 480 instrument (Roche, Basel, Switzerland). Primers were designed using Primer-BLAST ([@bib61]) or obtained from qPrimerDepot ([@bib11]) or from previously published sequences ([@bib35]). Primer sequences and source are listed in [Table 1](#table1){ref-type="table"}.
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###### RT-PCR primer sequences and source.

  Gene symbol   Forward primer            Reverse primer          Source
  ------------- ------------------------- ----------------------- ----------------
   NANOG        TCCAACATCCTGAACCTCAGC     ACCATTGCTATTCTTCGGCCA   Primer-BLAST
   OCT4         AAACCCACACTGCAGCAGAT      TGTGCATAGTCGCTGCTTGA    Primer-BLAST
   SOX2         TACAGCATGATGCAGGACCA      CCGTTCATGTAGGTCTGCGA    Primer-BLAST
   NODAL        AGACATCATCCGCAGCCTAC      CAAAAGCAAACGTCCAGTTCT   Primer-BLAST
   GAPDH        AATCCCATCACCATCTTCCA      TGGACTCCACGACGTACTCA    Primer-BLAST
   SMAD7        CCAGGCTCCAGAAGAAGTTG      CCAACTGCAGACTGTCCAGA    qPrimerDepot
   LEFTY1       CTCCATGCCGAACACCAG        GGAAAGAGGTTCAGCCAGAG    qPrimerDepot
   LEFTY2       TCAATGTACATCTCCTGGCG      CTGGACCTCAGGGACTATGG    qPrimerDepot
   BRA          CGTTGCTCACAGACCACAG       ATGACAATTGGTCCAGCCTT    qPrimerDepot
   GSC          GAGGAGAAAGTGGAGGTCTGGTT   CTCTGATGAGGACCGCTTCTG   Mendjan et al.
   EOMES        CACATTGTAGTGGGCAGTGG      CGCCACCAAACTGAGATGAT    Mendjan et al.

Total RNA-sequencing {#s4-9}
--------------------

RUES2 cells were seeded in 6-well plates (200,000 single cells per well) in E7 medium supplemented with 10 µM Rock-inhibitor and incubated overnight. On the following day the media was changed to E7 supplemented with 10 µM Rock-inhibitor with or without 10 ng/mL ACTIVIN A. Samples (three pooled-wells) were collected in 1 mL Trizol at 1, 2.5, 4, 8 and 12 hr for the ACTIVIN-treated conditions and after 0, 6 and 12 hr for the no-ACTIVIN conditions (to be used as negative controls). Total cellular RNA for each sample was extracted using RNeasy Mini Kit (QIAGEN) and 2 ug of total RNA was used to prepare each individual RNA-seq library. RNA-seq library construction was conducted with the TruSeq RNA Library Preparation Kit (Illumina, San Diego, CA) as per the manufacturer's instructions and sequenced in an Illumina HiSeq 2500 apparatus. Raw reads were mapped to hg19 using STAR aligner, and the gene read counts were normalized using the DESeq2 Bioconductor package ([@bib30]). Library preparation, sequencing, and mapping were performed by the New York Genome Center (New York, NY, USA). All raw data files are available from the GEO database (accession number GSE111717).

Image analysis {#s4-10}
--------------

For images acquired from micropatterned cell culture experiments, stitching and colony detection were carried out as described previously using custom software written in MATLAB ([@bib17]). For analysis of the SMAD reporter lines on micropatterned colonies a single z-plane through the middle of the colony was analyzed at each time point. Background in each channel was removed by subtracting a minimum intensity image that was generated by taking the minimum value at each pixel over all images in that channel in the same z-plane. Vignetting was corrected by dividing by a flat-field image that was generated by normalizing the intensity of the minimum image to 1. This procedure corrects the intensity drop-off at the border of the images without further altering the average image intensity.

Nuclei segmentation and signal quantification were performed on the corrected images as follows. The H2B image was thresholded to generate a binary image separating the foreground (nuclei) from the background. The original, corrected H2B image was then filtered with a median and sphere filter with parameters matching the expected size of individual nuclei. Local maxima corresponding to individual nuclei were detected using the MATLAB extended-maxima transform function. Maxima were dilated to increase the likelihood of obtaining a single maximum per nuclei. Maxima falling within the foreground were used as seeds for watershed segmentation, which was also restricted to the foreground and was used to obtain a labeled object corresponding to each nucleus within the image. The segmented objects were further processed to eliminate objects much larger or smaller than the expected size of individual nuclei. The results of the segmentation were used as a mask to obtain the median per cell nuclear intensity in each channel. Images acquired from fixed samples that were stained by immunofluorescence were similarly segmented and analyzed. The DAPI channel was used to perform nuclei segmentation, and the segmented objects were subsequently used to obtain the median per cell signal intensity in each channel.

For the mCitrine-SMAD2 reporter line an enrichment of the mCitrine signal in the cytoplasm relative to the nucleus prior to ligand presentation could be detected, which decreased concomitantly with an increase in the nuclear signal following ACTIVIN presentation. Therefore, the mCitrine-SMAD2 response was quantified as the nuclear-to-cytoplasmic ratio, which was used previously as a readout for TGFβ pathway activity ([@bib56]). In order to estimate the cytoplasmic signal for each cell, a narrow donut surrounding the nuclear mask was formed by dilating the nuclear mask once by an inner radius and a second time by an outer radius and subtracting the first dilated object from the second. The donut, which formed the cytoplasmic mask, was not restricted to the foreground pixels (H2B signal), but it was prevented from overlapping with the masks of neighboring nuclei. The median mCitrine intensity within the nuclear mask was divided by the median intensity within the cytoplasmic mask on a per cell basis. The qualitative behavior of the SMAD2 nuclear-to-cytoplasmic response was not sensitive to the exact size of the inner and outer radius of the donut. Therefore, the values were chosen manually and kept fixed throughout all analyses. For the RFP-SMAD1 reporter line a faint nuclear signal could be detected prior to ligand presentation. However, no cytoplasmic signal could be detected above the background. Therefore, the RFP-SMAD1 response was quantified as the median nuclear signal normalized to the median H2B signal to normalize for cells moving in and out of the z-plane. In order to analyze the SMAD response as a function of radial position within the micropatterned colonies, the cells within a single colony were binned based on the radial position of their center and the average response per cell within each bin was calculated. The radial profile for individual colonies was then averaged over several colonies. Analysis of the SMAD reporter lines in single-cell culture was carried out in a similar manner. The maximum intensity projection image, rather than a single z-plane was analyzed. Since cells remained flat under these conditions it was not necessary to normalize the SMAD1 signal by H2B.

RNAseq analysis and clustering {#s4-11}
------------------------------

For each gene, a baseline expression profile, which was calculated using a linear interpolation between the 0, 6 and 12 hr control samples, was subtracted from the expression values of the ACTIVIN-treated samples. The gene list was filtered to contain only those genes that: (1) had at least one time point with an absolute fold-change larger than 2 (up- or down-regulated) compared to 0 hr and (2) had at least one time point with a normalized read count higher than 100. That generated a list of 3529 genes of interest, which was then hierarchically clustered by their z-scored expression values, using Cluster 3.0 ([@bib14]) with the following options: centered correlation as the similarity metric and average linkage as clustering method. The resulting hierarchical tree was visualized using Java TreeView ([@bib41]) to identify the minimal clusters of interest.

Motif analysis {#s4-12}
--------------

To identify motifs enriched within gene clusters, the 2000 bp upstream sequences for all genes were extracted using the PWMEnrich Bioconductor package. Motif enrichment of each cluster\'s sequence set was performed using AME ([@bib3]) with the HOCOMOCOv10 database ([@bib26]) against the background (upstream sequences of all genes).

Gene enrichment analysis {#s4-13}
------------------------

We assessed the enrichment of the genes in each of the groups identified in [Figure 4A](#fig4){ref-type="fig"} for previously defined marker gene sets from isolated endoderm, mesoderm, and ectoderm/epiblast tissue from E7.5 mouse embryos ([@bib31]) using the GOseq Bioconductor package ([@bib62]). Mouse genes were mapped to human orthologues using data downloaded from the Mouse Genome Informatics database (<http://www.informatics.jax.org/downloads/reports/HOM_MouseHumanSequence.rpt>).

Data and software availability {#s4-14}
------------------------------

The RNA-sequencing data related to [Figure 4](#fig4){ref-type="fig"} and discussed in this publication have been deposited in NCBI\'s Gene Expression Omnibus ([@bib16]) and are accessible through GEO Series accession number GSE111717 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111717>). Image analysis software StemCellTracker (commit no. 1c31fdd) is available through GitHub ([@bib25]; copy archived at <https://github.com/elifesciences-publications/StemCellTracker>).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"WNT signaling memory is required for ACTIVIN to function as a morphogen in human gastruloids\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Aviv Regev as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The work described in this manuscript is based on the manipulation of a very useful in vitro human \"gastruloid\" system that the Brivanlou and Siggis labs have developed. In this case, experiments are directed at clarifying the interactions between WNT and ACTIVIN signaling that serve to regulate the transition between pluripotency and differentiation. The main conclusion is that a relatively brief exposure to a WNT ligand modifies pluripotent cells such that they respond by differentiating when subsequently treated with ACTIVIN under conditions normally insufficient to trigger differentiation. That is, the \"memory\" of WNT signaling changes the response to ACTIVIN.

General Assessment:

The reviewers were uniformly enthusiastic about the quality of the work in the manuscript, as well as its potential for clarifying some aspects of signaling during early development, particularly early human development. The reviewers\' comments fall into two general categories. The first requires some additional experiments to clarify some details of the quantification applied to your imaging results and the use of small molecule inhibitors. The second asks for some revisions in the text and, perhaps, some changes in the manner in which certain of your conclusions are stated.

Required revisions requiring additional work:

Use of reagents and quantification:

1\) Can the authors clarify the effects of small molecules singly and in combination on the total number of cells to determine if there were any effects related to toxicity?

2\) Figure 2D, G; Figure 3C, E, G: Isn\'t the relevant metric the number of cells with positive nuclear stain?

3\) Subsection "Single-cell response dynamics reflect the behavior at the edge of gastruloids": Can the authors clarify how they define SMAD2 baseline and, therefore, how they determine the percent of cells above baseline?

4\) Subsection "WNT memory stabilizes the mesendodermal transcriptional response to ACTIVIN", first paragraph and Figure 7: What is the evidence that IWP-2 continues to block WNT secretion for 48 hrs?

Other aspects of data interpretation/metrics:

1\) The conclusion that ACTIVIN alone does not induce mesoderm relies on just three markers (BRA, EOMES and GSC) and the persistence of some markers associated with pluripotency (yet most do not seem very specific to a pluripotent state, they resemble more of an ACTIVIN response). Is there additional evidence for lack of mesoderm induction by ACTIVIN alone (perhaps in the RNA-seq data)? The lack of induction is at odds with the ability of ACTIVIN, NODAL or NODAL/Vg1 alone to induce non-organizer mesoderm in the absence of a β-catenin signal in amphibian (animal cap) and mammalian cells. The authors discuss this important point but is the apparent discrepancy between systems due to the inability to separate endogenous WNT from ACTIVIN/NODAL/Vg signals or possibly an evolutionary difference between mammalian and non-mammalian systems? How similar is mesendoderm induced by WNT+ACTIVIN to \"natural\" mammalian (mouse) or even nonmammalian mesendoderm? It seems gene expression data associated with Figure 4 could be compared to published datasets or previous characterizations.

2\) Can the authors detail how many biological replicates underpin each major experiment?

Revisions that do not require additional experiments:

1\) Why was ACTIVIN used as the agent to induce SMAD2 signaling in the experiments? Is not NODAL(s) the more relevant ligand \"in vivo\"? Certainly real human embryos are off limits to providing a direct answer, but in hESCs are endogenous ACTIVIN or NODAL genes induced by mesendoderm-initiating WNT (or BMP) treatment? ACTIVIN and NODAL ligands are often used interchangeably to affect SMAD2/3 signaling in vertebrate embryonic cells or ESCs, but these different ligands can produce different effects, so a brief rationale for using ACTIVIN and not NODAL would be welcome.

2\) The authors should temper \"conclusions\" that go beyond the data presented. The authors tend to rule out SMAD3 engagement in the ACTIVIN response perhaps over-weighting the SMAD3 mutant studies. However, is there anything to rule out a simple redundancy between SMAD2/3 where either contributes? Insight from SMAD2 and SMAD2/3 mutant hESCs which are presumably on hand would help to settle this. The authors state \"Overall we conclude that cells maintain a memory of WNT exposure which makes them competent to differentiate in response to ACTIVIN (Figure 7E).\" this seems quite reasonable. However, the authors go on to write in the last sentence of the Results \"The molecular mechanism of this memory occurs through β-catenin-induced transcriptional changes as a modifier of SMAD2 signaling dynamics\". There is nothing to directly back this up: β-catenin was never studied, WNT transcriptional actions were not directly addressed, and the sentence is best deleted and possible mechanisms with supporting evidence left for discussion.
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Author response

> Required revisions requiring additional work:
>
> Use of reagents and quantification:
>
> 1\) Can the authors clarify the effects of small molecules singly and in combination on the total number of cells to determine if there were any effects related to toxicity?

No toxicity effect was observed on the total number of cells with any of the small molecules, SB (10 µM), endo-IWR1 (1 µM), or IWP2 (1 µM). Quantification of the total cell number in the experiments using small molecules has been added to Figure 5---figure supplement 1D and Figure 7B.

> 2\) Figure 2D, G; Figure 3C, E, G: Isn\'t the relevant metric the number of cells with positive nuclear stain?

We think that the average nuclear or nuclear-to-cytoplasmic intensity is the correct metric. To determine the number of positive nuclei requires a binary threshold, which discards data about the levels of the SMAD response that we can obtain from our live reporters. In all of our datasets, with the exception of SMAD1 on micropatterned colonies, the SMAD response is not binary and single cells respond with dynamics that are similar to the average response. This can be seen as a shift in the distribution (or histogram) of the response across all cells. We should have presented this data in our original manuscript. We have now added it in Figure 3---figure supplement 1. In the experiments in which we followed the SMAD1 response in micropatterned colonies, we were able to determine an on/off threshold. Therefore, following the reviewer's suggestion, we also quantified the number of SMAD1 positive cells and found results that are qualitatively similar to those presented in Figure 2D in which we present the average nuclear intensity as a function of time and position within the colony. This additional quantification is also now shown in Figure 2---figure supplement 2C--D.

> 3\) Subsection "Single-cell response dynamics reflect the behavior at the edge of gastruloids": Can the authors clarify how they define SMAD2 baseline and, therefore, how they determine the percent of cells above baseline?

We should have been more precise in our definition of the baseline. The baseline is defined by the average SMAD2 nuclear-to-cytoplasmic ratio at T \> 8 h after ACTIVIN presentation. This definition was previously included in Figure 3---figure supplement 1 and it has now been added to the Results subs "Single-cell response dynamics reflect the behavior at the edge of gastruloids".

> 4\) Subsection "WNT memory stabilizes the mesendodermal transcriptional response to ACTIVIN", first paragraph and Figure 7: What is the evidence that IWP-2 continues to block WNT secretion for 48 hrs?

The original paper reporting IWP2 (Chen et al., 2009) demonstrated complete inhibition of WNT by 24 hours of compound exposure in mammalian cells. In hESCs specifically (Blauwkamp et al., 2012), presenting IWP-2 and replacing it every 24 hours was also shown to completely inhibit WNT. We also replaced the IWP-2 every 24 hours, following previously published protocols, and this has been clarified in the Results subsection "WNT memory stabilizes the mesendodermal transcriptional response to ACTIVIN", and in the Materials and methods section.

In order to verify that the IWP-2 was functioning to block endogenous WNT at 1 µM, we tested it in a side-by-side experiment, in which micropatterned colonies were treated with BMP4 +/- IWP-2 (1 µM). In this context, mesendoderm is dependent on endogenous WNT production and signaling (Martyn et al., 2018). We find that mesendoderm is blocked by 1 µM IWP-2 in BMP4-treated micropatterned colonies. This data is presented in Figure 7---figure supplement 1B--C.

> Other aspects of data interpretation/metrics:
>
> 1\) The conclusion that ACTIVIN alone does not induce mesoderm relies on just three markers (BRA, EOMES and GSC) and the persistence of some markers associated with pluripotency (yet most do not seem very specific to a pluripotent state, they resemble more of an ACTIVIN response). Is there additional evidence for lack of mesoderm induction by ACTIVIN alone (perhaps in the RNA-seq data)? The lack of induction is at odds with the ability of ACTIVIN, NODAL or NODAL/Vg1 alone to induce non-organizer mesoderm in the absence of a β-catenin signal in amphibian (animal cap) and mammalian cells. The authors discuss this important point but is the apparent discrepancy between systems due to the inability to separate endogenous WNT from ACTIVIN/NODAL/Vg signals or possibly an evolutionary difference between mammalian and non-mammalian systems? How similar is mesendoderm induced by WNT+ACTIVIN to \"natural\" mammalian (mouse) or even nonmammalian mesendoderm. It seems gene expression data associated with Figure 4 could be compared to published datasets or previous characterizations.

Following the reviewer's advice, to further rule out mesoderm induction in our ACTIVIN only stimulation, we have also verified that canonical mammalian mesodermal markers such as HAND1, EVX1, MESP1, MESP2, MSGN, and TBX6 are not induced (Figure 4---source data 2). We take the oddity of lack of mesoderm induction by ACTIVIN alone in our system wholeheartedly, as we appreciate the importance of evaluating the relevance of our synthetic in vitro platform in modeling "natural" embryos. As the reviewer(s) has noted we address this important point in our Discussion section. We argue that while we cannot eliminate possible evolutionary differences in the fine-tuning of mesendodermal induction, we believe that our findings are in support of the classical experimental embryological discoveries made in the amphibian system. We state that "Although some mesoderm is induced in the ventral animal cap explants of *Xenopus*, only cells of the dorsal caps that have seen Wnt signals undergoes ACTIVIN-mediated induction of GSC+ mesendoderm". This is in agreement with our "cellular memory" of WNT signaling in our system.

Following the reviewer's suggestion, we additionally compared our RNA-seq dataset presented in Figure 4 with the tissue specific RNA-seq datasets of mouse embryos at E7.5 (Lu et al., 2018). This comparison showed that from the 3 groups defined in Figure 4, group 1 (transient induction following ACTIVIN presentation) displays the largest representation of endodermal genes, with 129 genes, out of 2,956 total in group 1, overlapping with the mouse endoderm gene set. This data along with the fact that GSC is induced under the WNT/ACTIVIN condition (RT-PCR and IF) suggests our mesendoderm is of dorso-anterior character. Group 2 (genes that are stably induced following ACTIVIN presentation) showed some enrichment of both endodermal (27) and mesodermal (15) genes, out of 452 total in group 2. Group 3 (genes that are down-regulated following ACTIVIN presentation) matched most closely primitive ectoderm/epiblast (5 genes), out of 121 total in group 3. This information has now been added to Figure 4---figure supplement 1B and the lists of overlapping genes have been added as Figure 4---source data 5.

> 2\) Can the authors detail how many biological replicates underpin each major experiment?

Two or more biological replicates were performed for each major experiment. This information was added to the figure legends.

Since the absolute intensity measurements from immunofluorescence can vary between experiments performed on different days, we only directly compared samples processed at the same time and these are presented as the nuclear intensity histograms shown on a single plot. In order to facilitate comparison across biological replicates processed and imaged on different days, we calculated the Kolmogorov-Smirnov distance between the cumulative distribution functions of each condition to a defined reference condition as described in the last paragraph of the subsection "Long-term, elevated SMAD2 baseline maintains pluripotency". The cumulative distribution function is calculated from the fluorescence intensity histogram. This type of analysis is robust to changes in imaging parameters, as long as the parameters are fixed between different conditions and their corresponding reference condition. Statistical tests were performed on KS distance estimates.

> Revisions that do not require additional experiments:
>
> 1\) Why was ACTIVIN used as the agent to induce SMAD2 signaling in the experiments? Is not NODAL(s) the more relevant ligand \"in vivo\"? Certainly real human embryos are off limits to providing a direct answer, but in hESCs are endogenous ACTIVIN or NODAL genes induced by mesendoderm-initiating WNT (or BMP) treatment? ACTIVIN and NODAL ligands are often used interchangeably to affect SMAD2/3 signaling in vertebrate embryonic cells or ESCs, but these different ligands can produce different effects, so a brief rationale for using ACTIVIN and not NODAL would be welcome.

The reviewer(s) is correct: the more relevant ligand "in vivo" in the mouse embryo is NODAL. Additionally, we have shown in Etoc et al. (2016) that BMP4 induces NODAL, in Martyn et al. (2018) that WNT induces NODAL, and in our present study that ACTIVIN also induces NODAL in a stable manner. We and others choose to use ACTIVIN rather than NODAL, because although both ligands differentiate hESCs towards the mesendoderm lineage, NODAL requires much higher concentrations to be effective (McLean et al., 2007). Following, the reviewer's recommendation we have now included this rational in the last paragraph of the Materials and methods subsection "Micropatterned cell culture".

> 2\) The authors should temper \"conclusions\" that go beyond the data presented. The authors tend to rule out SMAD3 engagement in the ACTIVIN response perhaps over-weighting the SMAD3 mutant studies. However, is there anything to rule out a simple redundancy between SMAD2/3 where either contributes? Insight from SMAD2 and SMAD2/3 mutant hESCs which are presumably on hand would help to settle this. The authors state \"Overall we conclude that cells maintain a memory of WNT exposure which makes them competent to differentiate in response to ACTIVIN (Figure 7E).\" this seems quite reasonable. However, the authors go on to write in the last sentence of the Results \"The molecular mechanism of this memory occurs through β-catenin-induced transcriptional changes as a modifier of SMAD2 signaling dynamics\". There is nothing to directly back this up: β-catenin was never studied, WNT transcriptional actions were not directly addressed, and the sentence is best deleted and possible mechanisms with supporting evidence left for discussion.

We are grateful to the reviewer(s) for pointing out two overreaching statements. First, it is correct that while our RUES2-SMAD3^-/-^ mutant does not change the response to ACTIVIN, we cannot rule out possible redundancy between SMAD2 and 3. We have, therefore, included this possibility in our interpretation in the subsection "SMAD3 is dispensable for the response of the adaptive and stable gene classes to ACTIVIN". Second, while we show that endo-IWR-1, which blocks WNT signaling at the level of β-catenin, does eliminate ACTIVIN-mediated mesendoderm induction, we did not provide *direct* evidence that the molecular mechanism underlying the memory occurs through β-catenin-induced transcriptional changes. Thus, we removed the sentence quoted by the reviewer from the text.
